Human Angiotensin II Receptor Gene Regulation
人血管紧张素 II 受体基因调控
基本信息
- 批准号:6436185
- 负责人:
- 金额:$ 21.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1992
- 资助国家:美国
- 起止时间:1992-08-01 至 2005-12-31
- 项目状态:已结题
- 来源:
- 关键词:RNA splicing affinity chromatography angiotensin II angiotensin receptor cell line fluorescence resonance energy transfer genetic regulation genetic transcription genetic translation messenger RNA polymerase chain reaction protein isoforms receptor expression ribosomes transcription factor transfection vascular smooth muscle
项目摘要
Abnormal growth of vascular smooth muscle cells (VSMC) is central to the pathophysiology of various cardiovascular diseases such as atherosclerosis, hypertension and restenosis after angioplasty. These abnormalities can be manifested as changes in the state of VSMC proliferation, differentiation, gene expression patterns and morphology. Currently, the peptide hormone, angiotensin II (Ang II), is believed to play a pivotal role in the development of hypertension and atherosclerosis since it acts as a growth promoting factor in VSMC. The biological responses to Ang II are mediated by its interaction with two distinct high affinity G protein-coupled receptors (GPCRs) now designated AT1R and AT2R. While characterizing the human AT1R (hAT1R) gene, it was demonstrated that human tissues can express at least eight alternatively spliced hAT1R mRNA transcripts which differ only in their 5'-untranslated regions (5'-UTR). Currently, very little is known about the functional significance of each splice variant or how they are regulated. Therefore, the long term goals of this project are to functionally characterize each splice variant and to investigate the molecular mechanisms that govern the expression of these mRNAs. An understanding of these processes is critical since aberrant transcriptional, post- transcriptional and/or translational regulation of hAT1R gene expression may result in the over-expression of the hAT1R which would lead to exaggerated Ang II responsiveness and possibly result in cardiovascular disease. The Specific Aims of this proposal are to: 1) Test the hypothesis that hAT1R mRNA splice variants are differentially expressed in human tissues and investigate the transcriptional regulation of the hAT1R gene by the distal and proximal promoter regions, 2) Test the hypothesis that hAT1R mRNA splice variants have distinct mRNA half-lives, which can be regulated by physiological stimuli, 3) Test the hypothesis that hAT1R mRNA splice variants are translated with different efficiencies, 4) Characterize the internal ribosome entry site (IRES) harbored in exon-1 of the hAT1R mRNA 5'-UTR and identify trans-acting factors which recognize this element, and 5) Test the hypothesis that "long" and "short" hAT1R isoforms can form hetero-dimers and that these hetero-dimers are functionally distinct.
血管平滑肌细胞(VSMC)的异常生长对于各种心血管疾病(例如动脉粥样硬化,高血压和血管成形症)等各种心血管疾病的病理生物学至关重要。 这些异常可以表现为VSMC增殖状态,分化,基因表达模式和形态的变化。 目前,据信肽激素激素II(ANG II)在高血压和动脉粥样硬化的发展中起关键作用,因为它是促进VSMC的生长因素。 对ANG II的生物反应是通过与现在指定为AT1R和AT2R的两个不同高亲和力G蛋白偶联受体(GPCR)的相互作用介导的。 在表征人AT1R(HAT1R)基因的同时,证明了人体组织至少可以表达八个剪接的HAT1R mRNA转录本,这些转录仅在其5'-非翻译区域(5'-utr)中有所不同。当前,对于每个剪接变体的功能重要性或它们的调节方式知之甚少。 因此,该项目的长期目标是在功能上表征每个剪接变体,并研究控制这些mRNA表达的分子机制。 对这些过程的理解至关重要,因为对HAT1R基因表达的异常转录,转录后和/或翻译调节可能会导致HAT1R的过表达,这会导致ANG ANG II的反应性夸大,并可能导致心血管疾病。 The Specific Aims of this proposal are to: 1) Test the hypothesis that hAT1R mRNA splice variants are differentially expressed in human tissues and investigate the transcriptional regulation of the hAT1R gene by the distal and proximal promoter regions, 2) Test the hypothesis that hAT1R mRNA splice variants have distinct mRNA half-lives, which can be regulated by physiological stimuli, 3) Test the hypothesis that hAT1R mRNA splice variants are translated with different efficiencies, 4) Characterize the internal ribosome entry site (IRES) harbored in exon-1 of the hAT1R mRNA 5'-UTR and identify trans-acting factors which recognize this element, and 5) Test the hypothesis that "long" and "short" hAT1R isoforms can form hetero-dimers and that these hetero-dimers are functionally distinct.
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
TERRY S ELTON其他文献
TERRY S ELTON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('TERRY S ELTON', 18)}}的其他基金
Novel Topoisomerase II alpha isoform as a drug resistance determinant
新型拓扑异构酶 II α 亚型作为耐药决定因素
- 批准号:
10297850 - 财政年份:2018
- 资助金额:
$ 21.9万 - 项目类别:
Novel Topoisomerase II alpha isoform as a drug resistance determinant
新型拓扑异构酶 II α 亚型作为耐药决定因素
- 批准号:
10057231 - 财政年份:2018
- 资助金额:
$ 21.9万 - 项目类别:
Novel Topoisomerase II alpha isoform as a drug resistance determinant
新型拓扑异构酶 II α 亚型作为耐药决定因素
- 批准号:
10531227 - 财政年份:2018
- 资助金额:
$ 21.9万 - 项目类别:
Training in Congenital and Acquired Heart Disease
先天性和后天性心脏病培训
- 批准号:
7762296 - 财政年份:2009
- 资助金额:
$ 21.9万 - 项目类别:
Training in Congenital and Acquired Heart Disease
先天性和后天性心脏病培训
- 批准号:
8126209 - 财政年份:2009
- 资助金额:
$ 21.9万 - 项目类别:
Training in Congenital and Acquired Heart Disease
先天性和后天性心脏病培训
- 批准号:
7939687 - 财政年份:2009
- 资助金额:
$ 21.9万 - 项目类别:
Human Angiotensin II Receptor Gene Regulation
人血管紧张素 II 受体基因调控
- 批准号:
6839442 - 财政年份:1992
- 资助金额:
$ 21.9万 - 项目类别:
相似国自然基金
基于亲和导向-邻近反应的复杂体系天然蛋白固定新方法及色谱评价
- 批准号:22374116
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
基于亲和色谱策略筛选和挖掘磷酸酶PP2A新型调节剂
- 批准号:22377149
- 批准年份:2023
- 资助金额:50.00 万元
- 项目类别:面上项目
基于仿生亲和色谱-质谱策略的肺结核患者血清抗体谱研究
- 批准号:82160027
- 批准年份:2021
- 资助金额:34 万元
- 项目类别:地区科学基金项目
基于亲和色谱靶点“钩钓”策略研究补肾活血方抗AGEs诱导神经损伤的作用机制
- 批准号:82104621
- 批准年份:2021
- 资助金额:24.00 万元
- 项目类别:青年科学基金项目
固定化单构象态受体亲和色谱的建立及止喘灵方平喘功效物质研究
- 批准号:82174088
- 批准年份:2021
- 资助金额:55.00 万元
- 项目类别:面上项目
相似海外基金
Soluble (pro)renin receptor regulation of kidney fibrosis
可溶性肾素(原)受体对肾纤维化的调节
- 批准号:
10745143 - 财政年份:2023
- 资助金额:
$ 21.9万 - 项目类别:
Domain-specific inhibition of angiotensin-converting enzyme as a therapeutic strategy for opioid use disorders
血管紧张素转换酶的域特异性抑制作为阿片类药物使用障碍的治疗策略
- 批准号:
10512191 - 财政年份:2022
- 资助金额:
$ 21.9万 - 项目类别:
Elucidating the transcriptional mechanisms that control the expression of the SARS-CoV-2 receptor ACE2
阐明控制 SARS-CoV-2 受体 ACE2 表达的转录机制
- 批准号:
10179069 - 财政年份:2021
- 资助金额:
$ 21.9万 - 项目类别:
The Role of 12-Lipoxygenase in Aldosterone Secretion
12-脂氧合酶在醛固酮分泌中的作用
- 批准号:
8957498 - 财政年份:2015
- 资助金额:
$ 21.9万 - 项目类别:
Development of a radioligand for assay of angiotensin-converting enzyme-2(ACE-2)
开发用于检测血管紧张素转换酶-2(ACE-2)的放射性配体
- 批准号:
8665091 - 财政年份:2013
- 资助金额:
$ 21.9万 - 项目类别: